Skip to main content

Effects of Etofibrate on Risk Factors of Atherosclerosis

  • Conference paper
Drugs Affecting Lipid Metabolism

Part of the book series: Proceedings in Life Sciences ((LIFE SCIENCES))

  • 211 Accesses

Abstract

For some time now the concept of the multifactorial genesis of atherosclerosis has been well accepted. Originally, it was based on the results of large epidemiological studies, which showed a powerful correlation between certain habits of life or metabolic or pathophysiological states, on the one hand, and the probability of contracting an atherosclerotic disease, on the other. The parameters of prognostic value were called risk factors. The 18-year follow-up of the Framingham study confirmed, among other factors; that serum cholesterol is a risk factor in the development of cardiovascular disease. In addition, different risk factors, when present at the same time, potentiate each other to an enormous risk. The coronary risk increases overproportionately with the blood cholesterol level, growing to a life-threatening danger in patients with familial homozygous hypercholesterolemia. An evaluation of the data of the Pooling Project by means of the Framingham HDL-risk-multipliers shows the incidence of fatal or nonfatal myocardial infarction to decrease in men at any concentration of total cholesterol by a factor of 2.5 as HDL-cholesterol increases from less than 40 mg dl-1 to more than 50 mg dl-1. For this reason the atherogenic index LDL-cholesterol/HDL-cholesterol beats the concentration of total cholesterol in estimating the coronary risk. Hyperlipoproteinemia is not only correlated with coronary vascular disease, but also with peripheral arterial acclusion disease (PAOD). In a group of patients with symptomatic PAOD, hyperlipoproteinemia was found in 76% of the patients, which was twice as much as in subjects without PAOD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV (1981) Studio a doppio cieco sull’at-tivita terapeutica di un nuovo farmaco ipolipemizzante: L’etofibrato. Clin Ther 96:31–38

    CAS  Google Scholar 

  • Betz E, Hämmerle H (1986) Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures. Drug Res 36:92–98

    CAS  Google Scholar 

  • Diehm C (1984) Carbohydrate-metabolism and fat-metabolism in normal persons and patients with peripheral arterial occlusive disease — the consequences of strenuous exercise. VASA J Vasc Dis (Suppl 13):1–61

    CAS  Google Scholar 

  • Ernst E (1986) Hämorheologie und zerebrale Insuffizienz. Therapiewoche 36:2514–2526

    Google Scholar 

  • Heinrich D, Thilo-Körner DGS, Roka L (1983) Die Bedeutung des Gefäßendothels für die Regulation der Fibrinolyse. Drug Res 33:1375–1378

    Google Scholar 

  • Hess H, Mietaschik A, Deichsel G (1985) Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 1:415–419

    Article  PubMed  CAS  Google Scholar 

  • Longenecker GL (1985) The platelets. Physiology and pharmacology. Academic Press, London New York Orlando

    Google Scholar 

  • Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC (1980) Relation between extent of coronary artery disease and blood viscosity. Br Med J 673:674

    Google Scholar 

  • Pfeiffer M, Tilsner V (1978) Der Einfluß von Etofibrat auf die Plasmaviskosität bei Hyperlipoprote-inämien. Med Klin 73:60–62

    PubMed  CAS  Google Scholar 

  • Schatton W, Holm E (1986) Etofibrat bei schweren diätrefraktären Fällen von Hyperlipoprotein-ämie. Fortschr Med 13:281–282

    Google Scholar 

  • Spöttl F, Forschauer J (1976) Influence of etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia. Atherosclerosis 25:293–301

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Seifert, T., Schatton, W. (1987). Effects of Etofibrate on Risk Factors of Atherosclerosis. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_72

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71702-4_72

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71704-8

  • Online ISBN: 978-3-642-71702-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics